Liu S, Lin M, Zhou X
Vaccines (Basel). 2025; 13(1).
PMID: 39852849
PMC: 11769387.
DOI: 10.3390/vaccines13010070.
Flores Malavet V, Dhume K, Satchmei A, Arvelo A, Beaird A, Annamalai S
J Clin Invest. 2025; 135(1).
PMID: 39744951
PMC: 11684801.
DOI: 10.1172/JCI179230.
Sircy L, Ramstead A, Gibbs L, Joshi H, Baessler A, Mena I
PLoS Pathog. 2024; 20(9):e1011639.
PMID: 39283916
PMC: 11404825.
DOI: 10.1371/journal.ppat.1011639.
Malouli D, Tiwary M, Gilbride R, Morrow D, Hughes C, Selseth A
Nat Commun. 2024; 15(1):6007.
PMID: 39030218
PMC: 11272155.
DOI: 10.1038/s41467-024-50345-6.
Hargrave K, Worrell J, Pirillo C, Brennan E, Masdefiol Garriga A, Gray J
Mucosal Immunol. 2024; 17(5):843-857.
PMID: 38851589
PMC: 11464401.
DOI: 10.1016/j.mucimm.2024.06.001.
Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection.
Lopez C, Zacharias Z, Ross K, Narasimhan B, Waldschmidt T, Legge K
NPJ Vaccines. 2024; 9(1):96.
PMID: 38822003
PMC: 11143372.
DOI: 10.1038/s41541-024-00883-3.
Opportunities and challenges for T cell-based influenza vaccines.
Mosmann T, McMichael A, LeVert A, McCauley J, Almond J
Nat Rev Immunol. 2024; 24(10):736-752.
PMID: 38698082
DOI: 10.1038/s41577-024-01030-8.
Ex Pluribus Unum: The CD4 T Cell Response against Influenza A Virus.
Finn C, McKinstry K
Cells. 2024; 13(7.
PMID: 38607077
PMC: 11012043.
DOI: 10.3390/cells13070639.
CD4 memory has a hierarchical structure created by requirements for infection-derived signals at an effector checkpoint.
Swain S
Front Immunol. 2023; 14:1306433.
PMID: 38152398
PMC: 10751922.
DOI: 10.3389/fimmu.2023.1306433.
Next-Generation Vaccines Against COVID-19 Variants: Beyond the Spike Protein.
Bonam S, Hu H
Zoonoses (Burlingt). 2023; 3(1).
PMID: 38031548
PMC: 10686570.
DOI: 10.15212/zoonoses-2023-0003.
Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses.
Rijnink W, Stadlbauer D, Puente-Massaguer E, Okba N, Kirkpatrick Roubidoux E, Strohmeier S
J Virol. 2023; 97(11):e0164622.
PMID: 37916834
PMC: 10688359.
DOI: 10.1128/jvi.01646-22.
A mosaic influenza virus-like particles vaccine provides broad humoral and cellular immune responses against influenza A viruses.
Liu X, Zhao T, Wang L, Yang Z, Luo C, Li M
NPJ Vaccines. 2023; 8(1):132.
PMID: 37679361
PMC: 10485063.
DOI: 10.1038/s41541-023-00728-5.
Multifunctional cytokine production marks influenza A virus-specific CD4 T cells with high expression of survival molecules.
Westerhof L, Noonan J, Hargrave K, Chimbayo E, Cheng Z, Purnell T
Eur J Immunol. 2023; 53(11):e2350559.
PMID: 37490492
PMC: 10947402.
DOI: 10.1002/eji.202350559.
SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.
Papadopoulou A, Karavalakis G, Papadopoulou E, Xochelli A, Bousiou Z, Vogiatzoglou A
Nat Med. 2023; 29(8):2019-2029.
PMID: 37460756
DOI: 10.1038/s41591-023-02480-8.
Pathogenicity and virulence of influenza.
Liang Y
Virulence. 2023; 14(1):2223057.
PMID: 37339323
PMC: 10283447.
DOI: 10.1080/21505594.2023.2223057.
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines.
Sunagar R, Singh A, Kumar S
Vaccines (Basel). 2023; 11(4).
PMID: 37112761
PMC: 10143972.
DOI: 10.3390/vaccines11040849.
CD4 Effector TCR Avidity for Peptide on APC Determines the Level of Memory Generated.
Jones M, Castonguay C, Nanaware P, Weaver G, Stadinski B, Kugler-Umana O
J Immunol. 2023; 210(12):1950-1961.
PMID: 37093656
PMC: 10247507.
DOI: 10.4049/jimmunol.2200337.
Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG.
Sanchez M, Ebensen T, Schulze K, Cargnelutti D, Scodeller E, Guzman C
Pharmaceutics. 2023; 15(3).
PMID: 36986773
PMC: 10057018.
DOI: 10.3390/pharmaceutics15030912.
STAT1 Controls the Functionality of Influenza-Primed CD4 T Cells but Therapeutic STAT4 Engagement Maximizes Their Antiviral Impact.
Finn C, Dhume K, Prokop E, Strutt T, McKinstry K
J Immunol. 2023; 210(9):1292-1304.
PMID: 36961447
PMC: 10121883.
DOI: 10.4049/jimmunol.2200407.
Intermediate Levels of Pre-Existing Protective Antibody Allow Priming of Protective T Cell Immunity against Influenza.
Ng T, Flores-Malavet V, Mansoor M, Arvelo A, Dhume K, Prokop E
J Immunol. 2023; 210(5):628-639.
PMID: 36645384
PMC: 9998374.
DOI: 10.4049/jimmunol.2200393.